Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors. METHODS: We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor. We assessed antitumor response and the safety and tolerability of the drug. Pharmacokinetics were assessed in a subgroup of patients. RESULTS: A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily. Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for technical reasons, response could not be evaluated in 7 patients (4.8 percent). No patient had a complete response to the treatment. The median duration of response had not been reached after a median follow-up of 24 weeks after the onset of response. Early resistance to imatinib was noted in 20 patients (13.6 percent). Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common. Gastrointestinal or intraabdominal hemorrhage occurred in approximately 5 percent of patients. There were no significant differences in toxic effects or response between the two doses. Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia. CONCLUSIONS: Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationDiagnosis of gastrointestinal stromal tumors: A consensus approach
Fletcher, C. D. M., Berman, J. J., Corless, C., Gorstein, F., Lasota, J., Longley, B. J., Miettinen, M., O'Leary, T. J., Remotti, H., Rubin, B. P., et al. (2002) · Human Pathology · doi:10.1053/hupa.2002.123545 · Cited by 3,419
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationTwo Hundred Gastrointestinal Stromal Tumors: Recurrence Patterns and Prognostic Factors for Survival
DeMatteo, R. P., Lewis, J. J., Leung, D., Mudan, S. S., Woodruff, J. M., & Brennan, M. F. (2000) · Annals of Surgery · doi:10.1097/00000658-200001000-00008 · Cited by 2,554
Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S. L., Capdeville, R., Dimitrijevic, S., Druker, B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,037
Self-citationBuchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Self-citationvan Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., di Paola, E. D., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06535-7 · Cited by 1,264
Self-citationHeinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,071
Self-citation
Research works printed but not linked: 4
- Rubin BP, 2001, Cancer Res, 61, 8118
- Goss GA, 2000, Prog Proc Am Soc Clin Oncol, 19, 599a
- Buchdunger E, 2000, J Pharmacol Exp Ther, 295, 139
- Peng B, 2001, Prog Proc Am Soc Clin Oncol, 20, 71a
Cited by
Items 301–400 of 1,007
Tyrosine kinase receptors as attractive targets of cancer therapy
Bennasroune, A., Gardin, A., Aunis, D., Crémel, G., & Hubert, P. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.08.004 · Cited by 197
Judson, I., Ma, P., Peng, B., Verweij, J., Racine, A., di Paola, E. D., van Glabbeke, M., Dimitrijevic, S., Scurr, M., Dumez, H., et al. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0876-0 · Cited by 193
Self-citationKinoshita, K., Hirota, S., Isozaki, K., Ohashi, A., Nishida, T., Kitamura, Y., Shinomura, Y., & Matsuzawa, Y. (2004) · The Journal of Pathology · doi:10.1002/path.1487 · Cited by 194
Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib
Stegmeier, F., Warmuth, M., Sellers, W. R., & Dorsch, M. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.297 · Cited by 192
Population pharmacokinetics of imatinib and the role of α1‐acid glycoprotein
Widmer, N., Decosterd, L. A., Csajka, C., Leyvraz, S., Duchosal, M. A., Rosselet, A., Rochat, B., Eap, C. B., Henry, H., Biollaz, J., et al. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02719.x · Cited by 196
Gastrointestinal stromal tumors: what do we know now?
Corless, C. L. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.173 · Cited by 193
Self-citationKang, Y.-K., Ryu, M.-H., Yoo, C., Ryoo, B.-Y., Kim, H. J., Lee, J. J., Nam, B.-H., Ramaiya, N., Jagannathan, J., & Demetri, G. D. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70453-4 · Cited by 191
Self-citationResponse of extraabdominal desmoid tumors to therapy with imatinib mesylate
Mace, J., Sybil Biermann, J., Sondak, V., McGinn, C., Hayes, C., Thomas, D., & Baker, L. (2002) · Cancer · doi:10.1002/cncr.11029 · Cited by 193
Pollack, I. F., Jakacki, R. I., Blaney, S. M., Hancock, M. L., Kieran, M. W., Phillips, P., Kun, L. E., Friedman, H., Packer, R., Banerjee, A., et al. (2007) · Neuro-Oncology · doi:10.1215/15228517-2006-031 · Cited by 192
Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
Vigarios, E., Epstein, J. B., & Sibaud, V. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3629-4 · Cited by 189
Rutkowski, P., Nowecki, Z., Nyckowski, P., Dziewirski, W., Grzesiakowska, U., Nasierowska‐Guttmejer, A., Krawczyk, M., & Ruka, W. (2006) · Journal of Surgical Oncology · doi:10.1002/jso.20466 · Cited by 187
Indications for Imatinib Mesylate Therapy and Clinical Management
Guilhot, F. (2004) · The Oncologist · doi:10.1634/theoncologist.9-3-271 · Cited by 190
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E., Gedye, C., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 187
Methodological and practical challenges for personalized cancer therapies
Wistuba, I. I., Gelovani, J. G., Jacoby, J. J., Davis, S. E., & Herbst, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.2 · Cited by 189
Short interfering RNAs as a tool for cancer gene therapy
Izquierdo, M. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700791 · Cited by 190
Joensuu, H., Wardelmann, E., Sihto, H., Eriksson, M., Sundby Hall, K., Reichardt, A., Hartmann, J. T., Pink, D., Cameron, S., Hohenberger, P., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5751 · Cited by 187
Self-citationDetermining the optimal dose in the development of anticancer agents
Mathijssen, R. H. J., Sparreboom, A., & Verweij, J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.40 · Cited by 184
Boussios, S., Pentheroudakis, G. E., Katsanos, K. H., & Pavlidis, N. A. (2012) · PubMed Central · Cited by 200
Perez, E. A., Livingstone, A. S., Franceschi, D., Rocha-Lima, C., Lee, D. J., Hodgson, N., Jorda, M., & Koniaris, L. G. (2006) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2006.01.002 · Cited by 185
Casali, P. G., Jost, L., Reichardt, P., Schlemmer, M., & Blay, J.-Y. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn080 · Cited by 187
Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor
Li, J., Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), D. O. G. O., Ye, Y., Wang, J., Zhang, B., Qin, S., Shi, Y., He, Y., Liang, X., Liu, X., et al. (2017) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2017.04.01 · Cited by 185
Involvement of platelet‐derived growth factor ligands and receptors in tumorigenesis
Heldin, C. ‐., Lennartsson, J., & Westermark, B. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12690 · Cited by 181
Phase II study of imatinib in patients with small cell lung cancer.
Johnson, B. E., Fischer, T. H., Fischer, B., Dunlop, D. J., Rischin, D., Silberman, S., Kowalski, M. O., Sayles, D., Dimitrijević, S., Fletcher, C. D. �., et al. (2003) · PubMed · Cited by 192
Self-citationCasali, P. G., Jost, L., Reichardt, P., Schlemmer, M., & Blay, J.-Y. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp131 · Cited by 182
Pawlik, T. M. (2006) · Archives of Surgery · doi:10.1001/archsurg.141.6.537 · Cited by 182
Nishino, M., Jagannathan, J. P., Krajewski, K. M., O’Regan, K., Hatabu, H., Shapiro, G., & Ramaiya, N. H. (2012) · American Journal of Roentgenology · doi:10.2214/ajr.11.7483 · Cited by 180
Prediction of Resistance to Small Molecule FLT3 Inhibitors
Cools, J., Mentens, N., Furet, P., Fabbro, D., Clark, J. J., Griffin, J. D., Marynen, P., & Gilliland, D. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2148 · Cited by 178
Gainor, J. F., Tan, D. S. W., De Pas, T., Solomon, B. J., Ahmad, A., Lazzari, C., de Marinis, F., Spitaleri, G., Schultz, K., Friboulet, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3009 · Cited by 177
A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands
Pfeffer, M. R., Talmi, Y., Catane, R., Symon, Z., Yosepovitch, A., & Levitt, M. (2007) · Oral Oncology · doi:10.1016/j.oraloncology.2005.12.026 · Cited by 178
Berthou, S., Aebersold, D. M., Schmidt, L. S., Stroka, D., Heigl, C., Streit, B., Stalder, D., Gruber, G., Liang, C., Howlett, A. R., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207691 · Cited by 178
McAuliffe, J. C., Hunt, K. K., Lazar, A. J. F., Choi, H., Qiao, W., Thall, P., Pollock, R. E., Benjamin, R. S., & Trent, J. C. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0177-7 · Cited by 181
The role of KIT in the management of patients with gastrointestinal stromal tumors
Hornick, J. L., & Fletcher, C. D. M. (2007) · Human Pathology · doi:10.1016/j.humpath.2007.03.001 · Cited by 177
Self-citationThymic Carcinoma with Overexpression of Mutated KIT and the Response to Imatinib
Ströbel, P., Hartmann, M., Jakob, A., Mikesch, K., Brink, I., Dirnhofer, S., & Marx, A. (2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502523 · Cited by 176
Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond
Mankoff, D. A., Eary, J. F., Link, J. M., Muzi, M., Rajendran, J. G., Spence, A. M., & Krohn, K. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0074 · Cited by 175
Robust exchangeability designs for early phase clinical trials with multiple strata
Neuenschwander, B., Wandel, S., Roychoudhury, S., & Bailey, S. (2016) · Pharmaceutical Statistics · doi:10.1002/pst.1730 · Cited by 175
Lee, S. H., Lopes de Menezes, D., Vora, J., Harris, A., Ye, H., Nordahl, L., Garrett, E., Samara, E., Aukerman, S. L., Gelb, A. B., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2129 · Cited by 174
2023 GEIS Guidelines for gastrointestinal stromal tumors
Serrano, C., Martín‐Broto, J., Asencio, J. M., López‐Guerrero, J. A., Rubió‐Casadevall, J., Bagué, S., del Muro, X. G., Fernández-Hernández, J., Herrero, L., Pousa, A. L., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231192388 · Cited by 190
A conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity
Levinson, N. M., & Boxer, S. G. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1404 · Cited by 171
Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series
Dresemann, G. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi317 · Cited by 174
Bauer, S., Hartmann, J. T., de Wit, M., Lang, H., Grabellus, F., Antoch, G., Niebel, W., Erhard, J., Ebeling, P., Zeth, M., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21164 · Cited by 173
DeMatteo, R. P., Ballman, K. V., Antonescu, C. R., Corless, C., Kolesnikova, V., von Mehren, M., McCarter, M. D., Norton, J., Maki, R. G., Pisters, P. W. T., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e3182a15eb7 · Cited by 173
Self-citationFamilial Gastrointestinal Stromal Tumor Syndrome: Phenotypic and Molecular Features in a Kindred
Li, F. P., Fletcher, J. A., Heinrich, M. C., Garber, J. E., Sallan, S. E., Curiel-Lewandrowski, C., Duensing, A., van de Rijn, M., Schnipper, L. E., & Demetri, G. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.009 · Cited by 174
Self-citationChen, J., DeAngelo, D. J., Kutok, J. L., Williams, I. R., Lee, B. H., Wadleigh, M., Duclos, N., Cohen, S., Adelsperger, J., Okabe, R., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404438101 · Cited by 171
Self-citationImatinib-Induced Regression of AIDS-Related Kaposi's Sarcoma
Koon, H. B., Bubley, G. J., Pantanowitz, L., Masiello, D., Smith, B., Crosby, K., Proper, J., Weeden, W., Miller, T. E., Chatis, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.079 · Cited by 171
Opportunities and challenges in the development of kinase inhibitor therapy for cancer
Sawyers, C. L. (2003) · Genes & Development · doi:10.1101/gad.1152403 · Cited by 170
Bauer, S., Rutkowski, P., Hohenberger, P., Miceli, R., Fumagalli, E., Siedlecki, J. A., Nguyen, B.-P., Kerst, M., Fiore, M., Nyckowski, P., et al. (2014) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2013.12.020 · Cited by 168
Serrano, C., Mariño-Enríquez, A., Tao, D. L., Ketzer, J., Eilers, G., Zhu, M., Yu, C., Mannan, A. M., Rubin, B. P., Demetri, G. D., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0389-6 · Cited by 167
Self-citationImpact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era
Bonvalot, S., Eldweny, H., Péchoux, C. L., Vanel, D., Terrier, P., Cavalcanti, A., Robert, C., Lassau, N., & Cesne, A. L. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9047-3 · Cited by 167
Holdsworth, C. H., Badawi, R. D., Manola, J. B., Kijewski, M. F., Israel, D. A., Demetri, G. D., & Van den Abbeele, A. D. (2007) · American Journal of Roentgenology · doi:10.2214/ajr.07.2496 · Cited by 167
Self-citationKinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies
Bikker, J. A., Brooijmans, N., Wissner, A., & Mansour, T. S. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8010542 · Cited by 166
Monitoring response to treatment in patients utilizing PET
Avril, N. E., & Weber, W. A. (2005) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2004.09.006 · Cited by 171
Falchook, G. S., Trent, J. C., Heinrich, M. C., Beadling, C., Patterson, J., Bastida, C. C., Blackman, S. C., & Kurzrock, R. (2013) · Oncotarget · doi:10.18632/oncotarget.864 · Cited by 169
Self-citationDemetri, G. D., Antonia, S., Benjamin, R. S., Bui, M. M., Casper, E. S., Conrad, E. U., DeLaney, T. F., Ganjoo, K. N., Heslin, M. J., Hutchinson, R. J., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0049 · Cited by 164
Self-citationAppel, S., Boehmler, A. M., Grünebach, F., Müller, M. R., Rupf, A., Weck, M. M., Hartmann, U., Reichardt, V. L., Kanz, L., Brümmendorf, T. H., et al. (2004) · Blood · doi:10.1182/blood-2003-03-0975 · Cited by 163
Gastrointestinal stromal tumors: Clinical profile, pathogenesis, treatment strategies and prognosis
NOWAIN, A., BHAKTA, H., PAIS, S., KANEL, G., & VERMA, S. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.03720.x · Cited by 164
Pharmacodynamic Biomarkers for Molecular Cancer Therapeutics
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)96008-4 · Cited by 161
Delbaldo, C., Chatelut, E., Ré, M., Deroussent, A., Séronie-Vivien, S., Jambu, A., Berthaud, P., Le Cesne, A., Blay, J.-Y., & Vassal, G. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2596 · Cited by 162
Trudel, S., Ely, S., Farooqi, Y., Affer, M., Robbiani, D. F., Chesi, M., & Bergsagel, P. L. (2004) · Blood · doi:10.1182/blood-2003-10-3650 · Cited by 162
Costa, D. B., Kobayashi, S., Tenen, D. G., & Huberman, M. S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.05.017 · Cited by 160
“The success of such an oncogene-targeted approach for cancer therapy has been fulfilled in chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST) [13,14].”
BackgroundSunitinib treatment in pediatric patients with advanced GIST following failure of imatinib
Janeway, K. A., Albritton, K. H., Van Den Abbeele, A. D., D'Amato, G. Z., Pedrazzoli, P., Siena, S., Picus, J., Butrynski, J. E., Schlemmer, M., Heinrich, M. C., et al. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.21909 · Cited by 162
Self-citationWen, P. Y., Yung, W. K. A., Lamborn, K. R., Norden, A. D., Cloughesy, T. F., Abrey, L. E., Fine, H. A., Chang, S. M., Robins, H. I., Fink, K., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-010 · Cited by 162
Bolton, A. E., Peng, B., Hubert, M., Krebs-Brown, A., Capdeville, R., Keller, U., & Seiberling, M. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0722-9 · Cited by 160
Self-citationPrognostic factors after surgery of primary resectable gastrointestinal stromal tumours
Aparicio, T., Boige, V., Sabourin, J.-C., Crenn, P., Ducreux, M., Le Cesne, A., & Bonvalot, S. (2004) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2004.06.016 · Cited by 160
The role of genetic testing in soft tissue sarcoma
Antonescu, C. R. (2006) · Histopathology · doi:10.1111/j.1365-2559.2005.02285.x · Cited by 160
Garner, A. P., Gozgit, J. M., Anjum, R., Vodala, S., Schrock, A., Zhou, T., Serrano, C., Eilers, G., Zhu, M., Ketzer, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1397 · Cited by 158
Self-citationRationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
Park, J. W., Kerbel, R. S., Kelloff, G. J., Barrett, J. C., Chabner, B. A., Parkinson, D. R., Peck, J., Ruddon, R. W., Sigman, C. C., & Slamon, D. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0785 · Cited by 159
Drug Transporters and Imatinib Treatment: Implications for Clinical Practice
Eechoute, K., Sparreboom, A., Burger, H., Franke, R. M., Schiavon, G., Verweij, J., Loos, W. J., Wiemer, E. A. C., & Mathijssen, R. H. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2250 · Cited by 160
Shankar, S., vanSonnenberg, E., Desai, J., DiPiro, P. J., Van Den Abbeele, A., & Demetri, G. D. (2005) · Radiology · doi:10.1148/radiol.2353040332 · Cited by 160
Self-citationHartmann, K., Wardelmann, E., Ma, Y., Merkelbach–Bruse, S., Preussner, L. M., Woolery, C., Baldus, S. E., Heinicke, T., Thiele, J., Buettner, R., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.060 · Cited by 157
Methyl-containing pharmaceuticals: Methylation in drug design
Sun, S., & Fu, J. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.09.016 · Cited by 174
BRAF as a potential therapeutic target in melanoma and other malignancies
Tuveson, D. A., Weber, B. L., & Herlyn, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00189-2 · Cited by 157
Self-citationMolecular-genetic imaging: current and future perspectives
Blasberg, R. G., & Gelovani, J. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18855 · Cited by 156
Prior, J. O., Montemurro, M., Orcurto, M.-V., Michielin, O., Luthi, F., Benhattar, J., Guillou, L., Elsig, V., Stupp, R., Delaloye, A. B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2742 · Cited by 158
Long-term imatinib therapy promotes bone formation in CML patients
Fitter, S., Dewar, A. L., Kostakis, P., To, L. B., Hughes, T. P., Roberts, M. M., Lynch, K., Vernon-Roberts, B., & Zannettino, A. C. W. (2008) · Blood · doi:10.1182/blood-2007-07-104281 · Cited by 156
Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects
Dutreix, C., Peng, B., Mehring, G. H., Hayes, M., Capdeville, R., Pokorny, R., & Seiberling, M. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0832-z · Cited by 164
Self-citationHigh expression of peptide receptors as a novel target in gastrointestinal stromal tumours
Reubi, J. C., K�rner, M., Waser, B., Mazzucchelli, L., & Guillou, L. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1476-2 · Cited by 154
Therapeutic Implications of Germline Testing in Patients With Advanced Cancers
Stadler, Z. K., Maio, A., Chakravarty, D., Kemel, Y. M., Sheehan, M. R., Salo‐Mullen, E. E., Tkachuk, K. A., Fong, C. J., Nguyen, B., Erakky, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03661 · Cited by 176
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein
Krug, L. M., Crapanzano, J. P., Azzoli, C. G., Miller, V. A., Rizvi, N. A., Gomez, J. E., Kris, M. G., Pizzo, B., Tyson, L. B., Dunne, M., et al. (2005) · Cancer · doi:10.1002/cncr.21000 · Cited by 153
Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?
Mussi, C., Ronellenfitsch, U., Jakob, J., Tamborini, E., Reichardt, P., Casali, P. G., Fiore, M., Hohenberger, P., & Gronchi, A. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp310 · Cited by 152
Molecular mechanisms of oxidative stress‐induced carcinogenesis: From epidemiology to oxygenomics
Toyokuni, S. (2008) · IUBMB Life · doi:10.1002/iub.61 · Cited by 153
Pantaleo, M. A., Astolfi, A., Indio, V., Moore, R., Thiessen, N., Heinrich, M. C., Gnocchi, C., Santini, D., Catena, F., Formica, S., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr130 · Cited by 152
Self-citationGastrointestinal stromal tumors: From a surgical to a molecular approach
Rossi, C. R., D, S. M. M., Mencarelli, R., D, M. F. M., Pilati, P., Nitti, D., & Lise, M. (2003) · International Journal of Cancer · doi:10.1002/ijc.11374 · Cited by 150
Dy, G. K., Miller, A. A., Mandrekar, S. J., Aubry, M. C., Langdon, R. M., Morton, R. F., Schild, S. E., Jett, J. R., & Adjei, A. A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi365 · Cited by 151
Prognostic Significance of c-kit Mutation in Localized Gastrointestinal Stromal Tumors
Kim, T. W., Lee, H., Kang, Y., Choe, M. S., Ryu, M., Chang, H. M., Kim, J., Yook, J. H., Kim, B. S., & Lee, J. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0581 · Cited by 149
Hyman, D. M., Solit, D. B., Arcila, M. E., Cheng, D. T., Sabbatini, P., Baselga, J., Berger, M. F., & Ladanyi, M. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.08.005 · Cited by 148
Levinson, N. M., & Boxer, S. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029828 · Cited by 148
Ugurel, S., Mentzel, T., Utikal, J. S., Helmbold, P., Mohr, P., Pföhler, C., Schiller, M., Hauschild, A., Hein, R., Kämpgen, E., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1411 · Cited by 148
Ben‐Ami, E., Barysauskas, C. M., von Mehren, M., Heinrich, M. C., Corless, C. L., Butrynski, J. E., Morgan, J. A., Wagner, A. J., Choy, E., Yap, J. T., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw228 · Cited by 152
Self-citationSubramanian, S., West, R. B., Corless, C. L., Ou, W., Rubin, B. P., Chu, K., Leung, S. Y., Yuen, S. T., Zhu, S., Hernandez‐Boussard, T., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1208056 · Cited by 157
Self-citationPediatric Gastrointestinal Stromal Tumors
Pappo, A. S., & Janeway, K. A. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2008.11.005 · Cited by 152
Therapeutic targeting of c-KIT in cancer
Ashman, L. K., & Griffith, R. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.740010 · Cited by 147
Pathology of gastrointestinal stromal tumors
Hirota, S., & Isozaki, K. (2006) · Pathology International · doi:10.1111/j.1440-1827.2006.01924.x · Cited by 155
The role of companion diagnostics in the development and use of mutation-targeted cancer therapies
Papadopoulos, N., Kinzler, K. W., & Vogelstein, B. (2006) · Nature Biotechnology · doi:10.1038/nbt1234 · Cited by 161
Ewing's Sarcoma and Primitive Neuroectodermal Family of Tumors
Carvajal, R. D., & Meyers, P. A. (2005) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2005.03.004 · Cited by 164
A guide for the diagnosis and management of gastrointestinal stromal cell tumors
Sepe, P. S., & Brugge, W. R. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.43 · Cited by 162
Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies
Hamer, P. C. D. W. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop068 · Cited by 166
Soft Tissue Sarcoma, Version 2.2012: Featured Updates to the NCCN Guidelines
von Mehren, M., Benjamin, R. S., Bui, M. M., Casper, E. S., Conrad, E. U., DeLaney, T. F., Ganjoo, K. N., George, S., González, R., Heslin, M. J., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0099 · Cited by 149
Steeghs, N., Nortier, J. W. R., & Gelderblom, H. A. J. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9227-1 · Cited by 162
Kérob, D., Porcher, R., VEROLA, O., Dalle, S., Maubec, E., Aubin, F., D'Incan, M., Bodokh, I., Boulinguez, S., Madelaine, I., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3401 · Cited by 145
Improving the evaluation of new cancer treatments: challenges and opportunities
Rothenberg, M. L., Carbone, D. P., & Johnson, D. H. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1047 · Cited by 153
Metadata
- Authors
- Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., Fletcher, J. A., Silverman, S. G., Silberman, S. L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B. J., Corless, C., Fletcher, C. D. M., & Joensuu, H.
- Affiliations
- Harvard University (US)
- Oregon Health & Science University (US)
- Fox Chase Cancer Center (US)
- Novartis (Switzerland) (CH)
- University of Helsinki (FI)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08-15
- Volume
- 347
- Issue
- 7
- Pages
- 472-480
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2015015957
- Cited by
- 4,389
- References
- 21
- Citations by year
- 2026: 85 · 2025: 91 · 2024: 107 · 2023: 115 · 2022: 117 · 2021: 128 · 2020: 136 · 2019: 119 · 2018: 131 · 2017: 136 · 2016: 160 · 2015: 182 · 2014: 192 · 2013: 210 · 2012: 255
- FWCI
- 167.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- CRC Press eBooks (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- U.S. Department of Veterans Affairs
- Northwest Health Foundation
- Helsingin Yliopisto
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- imatinib mesylate, gastrointestinal stromal tumor, KIT receptor tyrosine kinase, tyrosine kinase inhibitors, antitumor immunity, drug resistance, pharmacokinetics, adverse effects, metastatic cancer, dose comparison
- MeSH terms
- Imatinib Mesylate, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Benzamides, Female, Gastrointestinal Neoplasms, Humans, Male, Middle Aged, Piperazines, Protein-Tyrosine Kinases, Pyrimidines, Remission Induction, Signal Transduction, Survival Analysis, Stromal Cells, Proto-Oncogene Proteins c-kit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.